Halyard Health, Inc. (HYH) Rating Reiterated by KeyCorp

Halyard Health, Inc. (NYSE:HYH)‘s stock had its “hold” rating reissued by equities researchers at KeyCorp in a report issued on Tuesday.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research report on Wednesday, July 12th. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price target on shares of Halyard Health in a research report on Thursday, September 21st. Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Deutsche Bank AG boosted their price target on shares of Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, BidaskClub raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.25.

Halyard Health (NYSE:HYH) traded down 0.0173% during trading on Tuesday, reaching $43.4025. 23,261 shares of the company’s stock traded hands. Halyard Health has a one year low of $31.59 and a one year high of $46.63. The company has a 50-day moving average price of $45.40 and a 200 day moving average price of $40.55. The firm has a market capitalization of $2.03 billion, a PE ratio of 41.7332 and a beta of 1.75.

Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The business had revenue of $399.20 million during the quarter, compared to analyst estimates of $399.16 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The company’s revenue for the quarter was down .2% compared to the same quarter last year. On average, analysts anticipate that Halyard Health will post $1.95 earnings per share for the current fiscal year.

WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://ledgergazette.com/2017/10/17/halyard-health-inc-hyh-rating-reiterated-by-keycorp.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after buying an additional 5,847,442 shares during the last quarter. Vanguard Group Inc. lifted its position in Halyard Health by 4.7% in the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after buying an additional 196,367 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Halyard Health by 19.3% in the second quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after buying an additional 507,893 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Halyard Health by 242.8% in the second quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after buying an additi

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research report on Wednesday, July 12th. Stifel Nicolaus reissued a “buy” rating and set a $45.00 price target on shares of Halyard Health in a research report on Thursday, September 21st. Stephens raised shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a research report on Thursday, August 3rd. Deutsche Bank AG boosted their price target on shares of Halyard Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, BidaskClub raised shares of Halyard Health from a “hold” rating to a “buy” rating in a research report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.25.

Halyard Health (NYSE:HYH) traded down 0.0173% during trading on Tuesday, reaching $43.4025. 23,261 shares of the company’s stock traded hands. Halyard Health has a one year low of $31.59 and a one year high of $46.63. The company has a 50-day moving average price of $45.40 and a 200 day moving average price of $40.55. The firm has a market capitalization of $2.03 billion, a PE ratio of 41.7332 and a beta of 1.75.

Halyard Health (NYSE:HYH) last released its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.14. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The business had revenue of $399.20 million during the quarter, compared to analyst estimates of $399.16 million. During the same quarter in the prior year, the firm earned $0.45 earnings per share. The company’s revenue for the quarter was down .2% compared to the same quarter last year. On average, analysts anticipate that Halyard Health will post $1.95 earnings per share for the current fiscal year.

WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://ledgergazette.com/2017/10/17/halyard-health-inc-hyh-rating-reiterated-by-keycorp.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after buying an additional 5,847,442 shares during the last quarter. Vanguard Group Inc. lifted its position in Halyard Health by 4.7% in the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after buying an additional 196,367 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Halyard Health by 19.3% in the second quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after buying an additional 507,893 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Halyard Health by 242.8% in the second quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after buying an additional 1,320,735 shares during the last quarter. Finally, State Street Corp lifted its position in Halyard Health by 7.5% in the second quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock valued at $66,872,000 after buying an additional 119,154 shares during the last quarter. 91.02% of the stock is currently owned by institutional investors.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply